Marvel Biosciences Corp.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MRVL.V | QNTM | PCSA | SILO | MNOV | ABVC | |
|---|---|---|---|---|---|---|
| Market cap | 8.11M | 14.21M | 5.41M | 2.93M | 71.37M | 26.69M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -0.3 | -0.5 | -1.9 | -2.8 | -2.3 |
| Price/book | -2.6 | 2.1 | -17.0 | 0.3 | 1.9 | 2.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −43.90% | −74.27% | −75.51% | −82.01% | +3.57% | −64.79% |
| Today | −4.35% | 0.00% | −0.26% | +3.91% | +2.11% | +1.51% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All MRVL.V news ›Marvel security firm collapses amid alleged underpayments
October 22, 2026 — 7:00pm A major security business appointed by the AFL to patrol Marvel Stadium has collapsed owing almost $2 million to the tax office, while a liquidator investigates claims that hundreds of staff did not receive award…
Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site
Marvel Biosciences Corp. and its wholly-owned subsidiary, Marvel Biotechnology Inc. , a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurodevelopmental disorders, is pleased to announce that…
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marv... Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and…
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Corp. and its wholly-owned subsidiary, Marvel Biotechnology Inc. , a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurodevelopmental disorders, is pleased to announce…
Marvel Biosciences Corp. Receives Notice of Allowance for Australian Patent Application Covering Composition of Matter for Mb-204
Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc. announced that the Australian patent application 2021235803 covering MB-204 was accepted on May 7, 2026. The patent... Biotechnology & Medical Research…
Marvel Biosciences Corp. announced that it has received CAD 1.598145 million in funding
On September 29, 2026, Marvel Biosciences Corp closed the transaction. In connection with the Offering, the Company paid finders fees of CAD 77,175.49 in cash commission and 494,737 finder's warrants ... Biotechnology & Medical Research…
Marvel Biosciences secures financial and strategic investment with 5 Horizon Ventures
Marvel Biosciences Corp: Marvel Biosciences secures financial and strategic investment with 5 Horizon Ventures Marvel Biosciences Corp - 5 Horizon Ventures to fund 15% of CRO costs for phase I... Biotechnology & Medical Research Marvel…
Marvel Biosciences Secures Financial Support For the Phase 1 Trial of MB-204
Published on 04/07/2026 at 11:31 am EDT Canada futures fall as higher yields weigh on sentiment October 08, 2026 at 05:40 am EDT Bond Markets Are Giving Stocks a Headache TSX posts steepest decline in four months as bond yields climb TSX…
Marvel Biosciences Closes Private Placement
Marvel Biosciences closed its non-brokered private placement raising CA$1.6 million, it said in a statement late Tuesday. The offering consisted of the issuance of 10.7-million units at CA$0.15... Biotechnology & Medical Research Marvel…
Marvel Biosciences Corp.: Latest Headlines - Toronto S.E. Stock Exchange
Find the latest highlights on Marvel Biosciences Corp. at the Toronto S.E. stock exchange. Highlights Marvel Biosciences Corp. Biotechnology & Medical Research All financial news and data tailored to specific country editions
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com16
- investingnews.com2
- markets.businessinsider.com1
- smh.com.au1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 22 articles, not a forecast.